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Abstract 31 
Mucopolysaccharidosis IVA (MPS IVA or Morquio A syndrome) is a lysosomal storage 32 
disease caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), 33 
leading to lysosomal storage of keratan sulfate (KS) and chondroitin-6-sulfate. Currently, 34 
enzyme replacement therapy (ERT) using an enzyme produced in CHO cells represents the 35 
main treatment option for MPS IVA patients. As an alternative, we reported the production 36 
of an active GALNS enzyme produced in the yeast Pichia pastoris (prGALNS), which 37 
showed internalization by cultured cells through a potential receptor-mediated process and 38 
similar post-translational processing as human enzyme. In this study, we further studied the 39 
therapeutic potential of prGALNS through the characterization of the N-glycosylation 40 
structure, in-vitro cell uptake and KS reduction, and in-vivo biodistribution and generation 41 
of anti-prGALNS antibodies. Taken together, these results represent an important step in 42 
the develop of a P. pastoris-based platform for production of a therapeutic GALNS for 43 
MPS IVA ERT.  44 
 45 
Keywords: Morquio A, Mucopolysaccharidosis IV A, GALNS, Pichia pastoris, 46 
glycosylations  47 
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1. INTRODUCTION 48 
Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome, OMIM 253000) is a 49 
genetic spondyloepipheseal dysplasia caused by mutations in the gene encoding for the 50 
lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS, EC 3.1.6.4) [1, 2]. 51 
GALNS is involved in the intracellular degradation of the glycosaminoglycans (GAGs) 52 
chondroitin-6-sulfate (C6S) and keratan sulfate (KS). GALNS deficiency leads to 53 
lysosomal accumulation of C6S and KS [1, 2]. Clinically, MPS IVA patients are 54 
characterized by short stature, corneal clouding, hypoplasia of the odontoid process, pectus 55 
carinatum, valvular heart disease, mild hepatomegaly, laxity of joints, kyphoscoliosis, and 56 
genu valgum without central nervous system impairment [1, 3]. Treatment of these patients 57 
was only symptomatic and supportive, and patients often require surgical correction of the 58 
skeletal abnormalities to give them a better quality of life [3, 4]. 59 
The first specific therapy for MPS IVA patients was approved in 2014, consisting of the 60 
intravenous administration of a recombinant enzyme produced in CHO cells (elosulfase 61 
alfa) at 2 mg/kg weekly [5]. The cellular uptake of this recombinant enzyme occurs through 62 
mannose-6-phosphate receptors (M6PR) [6, 7]. In vivo studies on wild-type mice showed 63 
that the enzyme is detected in the growth plate, heart valve tissues, and hepatocytes with a 64 
high dose and high administraton frequency (5 infusions of 10 mg/kg every other day)  [7]. 65 
ERT with a recombinant enzyme on MPS IVA mice provided a limited imptact on bone 66 
pathology, while the use of a bone-targeting GALNS enhanced the therapeutic efficacy in 67 
bone pathology [6, 8]. Phase III studies showed that a weekly intravenous administration of 68 
2.0 mg/kg during 24 weeks allowed a slight improvement in the 6-minute walk test and the 69 
reduction of urinary KS [9], as well as an improvement in the maximal voluntary 70 
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ventilation, performance of daily life activities, and height/growth rate [10]. Despite of this, 71 
elosulfase alfa still has several constraints including: i) limited effect on skeletal, corneal, 72 
and heart valvular tissues [11, 12], ii) a short enzyme half-life and rapid clearance, iii) 73 
immune response [13], and iv) the need of weekly 4-5 hours infusions. This restricts the use 74 
of this therapy due to cost-effectiveness concerns of elosulfase alfa [14]. Limitations of 75 
current therapy indicate an unmet need for new therapeutic strategies to improve and 76 
expand the treatment options for MPS IVA patients. 77 
To overcome some of above mentioned ERT issues, it has been alternatively proposed to 78 
produce recombinant GALNS in other hosts [15, 16]. In fact, several human lysosomal 79 
enzymes have been produced in plant cells, transgenic animals, and microorganisms 80 
including Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Yarrowia lipolytica 81 
and Ogataea minuta [17-20]. Among these hosts, yeasts represent an important platform 82 
for the production of recombinant proteins since they can grow in low-cost culture media, 83 
are easily manipulated, secrete the recombinant protein to the medium, and produce 84 
heterologous proteins with similar post-translational modifications (e.g. disulfide bonds and 85 
N-glycosylations) to those observed in human proteins [21]. These characteristics are 86 
important since it has been demonstrated that GALNS N-glycosylations are not required to 87 
produce an active enzyme, but for protein cellular uptake [22]. Although yeast N-88 
glycosylations have some differences in size and composition in comparison with those 89 
observed in human proteins, these N-glycosylations can be glyco-engineered to produce 90 
tailored or homogeneous structures [23]. Furthermore, recombinant human β-91 
hexosaminidases [16, 24], α-glucosidase [25], and lysosomal acid lipase [26, 27] produced 92 
in the yeast P. pastoris, have shown dose-dependent cell uptake without any additional 93 
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processing of their N-glycosylations, although this is mostly true for macrophage-lineage 94 
cells that express mannose receptors.  95 
Previously, we reported the characterization of a human recombinant GALNS produced in 96 
the methylotrophic yeast P. pastoris GS115 (prGALNS). This protein showed a high 97 
stability at pH 5.0 and low temperature (4°C), and its activity was enhanced when it was 98 
co-expressed with the sulfatase modifier factor 1 (SUMF1) cDNA. Furthermore, in vitro 99 
assays showed that prGALNS was taken up by HEK293 cells and human skin fibroblasts 100 
through a process potentially mediated by an endocytic pathway [28]. In this study, we 101 
further studied the therapeutic potential of prGALNS through the characterization of the N-102 
glycosylation structure, in-vitro cell uptake and KS reduction, and the evaluation of in-vivo 103 
biodistribution and generation of anti-prGALNS antibodies. 104 
 105 
2. MATERIALS AND METHODS 106 
2.1 Bioreactor cultures 107 
A P. pastoris GS115 (Invitrogen, Thermo Fisher Scientific, San Jose, CA, USA) strain, 108 
previously transformed with the human GALNS and SUMF1 (EC 3.10.1.1) cDNAs [28], 109 
was used to produce prGALNS. Cultures were performed at 1.65 L scale in a KLF 3.7 L 110 
reactor (Bioengineering AG, Switzerland) using a modified fermentation medium FM22 111 
(composition per liter: KH2PO4 25.74 g, (NH4)2SO4 3 g, K2SO4 8.58 g, CaSO4 2H2O 0.6 g, 112 
glycerol 40 g, MgSO4 7H2O 7.02 g, Biotin 4 × 10−5% w/v, supplemented with Pichia trace 113 
minerals PTM4 1.0 mL) [29]. Protein production was first done in a batch culture with 114 
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glycerol followed by a fed-batch induction phase with methanol, as previously described. 115 
Cultures were done at 28 °C and pH 5.0, under limited oxygen conditions, during 96 h [28].  116 
2.2 Crude protein extracts and enzyme purification 117 
prGALNS was purified from culture medium following a previously reported protocol [28]. 118 
Briefly, culture medium (~1.7 L) was filtered sequentially through 0.45 and 0.22 µm using 119 
polyether sulphone membranes (Pall Corp, Port Washington, NY, USA). Permeate was 120 
ultra-filtrated through a 30 kDa cut-off membrane (Millipore, Billerica, MA, USA). Then, 121 
the retentate was dialyzed in acetate buffer 25mM, pH 5.0. Finally, prGALNS was purified 122 
by a two-step process using a cation exchange chromatography followed by size exclusion 123 
chromatography, as previously described [22, 28]. Fractions with the highest GALNS 124 
activity were pooled, diafiltrated against 25 mM sodium acetate pH 5.0, and lyophilized. 125 
Protein purification was monitored by SDS–PAGE and GALNS activity. 126 
2.3 N-glycans analysis and exoglycosidase digestion 127 
Samples for N-glycan analyses were obtained from the supernatant of P. pastoris cultures 128 
at 2 mL scale grown in BMGY medium (yeast extract 1% p/v; peptone 2% p/v; potassium 129 
phosphate 100 mM pH 6.0; yeast nitrogen base 1.34%; biotin 4 × 10–5%; glycerol 1%) and 130 
cultured for 24 h at 28 °C and 200 RPM. Cells were recovered and resuspended in BMMY 131 
medium (potassium phosphate 100 mM pH 6.0; yeast nitrogen base 1.34%; biotin 132 
4 × 10−5%; methanol 0.5%), and cultured for 48 hours at 28 °C and 200 RPM. N-glycans 133 
were labeled with 8-aminopyrene-1.3.6-trisulphonic acid (APTS, Sigma Aldrich, St. Louis, 134 
MO, USA) according to a published method [30]. N-linked glycans were prepared by 135 
blotting on 96-well plate with PVDF membrane plates (Millipore, Bedford, UK), and 136 
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analyzed by carbohydrate electrophoresis with laser-induced fluorescence detection (CE-137 
LIF) using an ABI 3130 DNA sequencer as previously reported [30]. N-glycans structures 138 
are reported according to Jacobs et al. [31], who used the same glycosylation analysis 139 
methodology used in the present study. 140 
2.4 GALNS activity 141 
GALNS activity was assayed by using 4-methylumbelliferyl-β-D-galactopyranoside-6-142 
sulfate (Toronto Chemicals Research, North York, ON, Canada) as substrate [26]. One unit 143 
(U) was defined as the amount of enzyme catalyzing the production of 1 nmol of 4-144 
methylumbelliferone product per hour. Specific GALNS activity was expressed as U mg−1 145 
of protein as determined by BCA assay (Pierce™ Thermo scientific. Rockford, USA).  146 
2.5 Cellular uptake of recombinant GALNS 147 
The cellular uptake of prGALNS was assayed in HEK293 cells (ATCC CRL1573) and 148 
human skin MPS IVA fibroblasts, as previously described [22]. Cells were maintained in 149 
Dulbecco’s modified medium (DMEM, Gibco, Carlsbad, CA) supplemented with fetal 150 
bovine serum 15% (Eurobio, Les Ulis, Francia), penicillin 100 U mL−1 and streptomycin 151 
100 U mL−1 (Walkersville, MD, USA), at 37 °C in a CO2 incubator. Twenty-four hours 152 
before the experiment, 1 ×105 cells per well were seeded in 12-well plates, and the culture 153 
medium was replaced with fresh medium 2 h before the experiment. The purified enzyme 154 
was added to a final concentration of 50 nM in HEK293 and 50, 100, and 200 nM in MPS 155 
IVA fibroblasts [22, 28]. Assays with HEK293 cells were performed with and without 156 
mannose-6-phosphate (M6P) or methyl α-D-mannopyranoside as inhibitors of M6P and 157 
mannose receptor, respectively, at a final concentration of 2 mM, according to a reported 158 
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study for recombinant GALNS produced in CHO cells [32]. After 6 h incubation, the 159 
culture medium was removed and the cells were washed three times with cold 1x PBS. 160 
Cells were lysed using 1% sodium deoxycholate (Sigma-Aldrich, St. Louis, MO, USA). 161 
The enzyme activity was determined in the cell lysate. All assays were performed in 162 
triplicate.  163 
2.6 Intracellular trafficking  164 
HEK293 cells were cultured on coverslips at 2 x104 cells per well, previously treated with 165 
0.01% (w/v) type II collagen (Sigma-Aldrich, St. Louis, MO, USA), with complete DMEM 166 
medium, as described above. Culture medium was replaced with fresh medium 1 h before 167 
the experiment and prGALNS, previously labeled with AlexaFluor 568 (Molecular Probes, 168 
Thermo Fisher Scientific, San Jose, CA, USA) according to manufacturer's protocol, was 169 
added at a final concentration of 50 nM. After 12 h of incubation with the labeled enzyme, 170 
the lysosomes were stained with Lysotracker® Green DND-26 (Molecular Probes, Thermo 171 
Fisher Scientific, San Jose, CA, USA) following the manufacturer’s protocol. Cells were 172 
then fixed using freshly prepared 4% paraformaldehyde in 1x PBS for 20 min at room 173 
temperature. The cellular nucleus was stained with 4´,6-diamidino-2-phenylindole 174 
dichydrochloride (DAPI, Thermo Fisher Scientific, San Jose, CA, USA). Cells were 175 
imaged using an Olympus FV1000 confocal microscope equipped with 405, 473 and 559 176 
nm laser lines using a 63×/1.49 NA oil objective. DAPI (excitation 382-393, emission 417-177 
477 nm), FITC (excitation 460-500 nm, emission 510-560 nm) and TRITC HyQ filter sets 178 
(excitation 530-560 nm, emission 590-650 nm) were applied to collect DAPI, 179 
Lysotracker® Green, and Alexa 568 signals, respectively. Images were processed by using 180 
NIH Image J 1.8.0 [33]. 181 
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2.7 In vitro keratan sulfate clearance assay 182 
MPS IVA skin fibroblasts were cultured and treated with 50, 100, and 200 nM of purified 183 
prGALNS. Quantification of di-KS in the cell lysate was done by liquid chromatography 184 
coupled to a tandem mass spectrometry (LC-MS/MS), as previously described [34, 35], 185 
with some modifications. Briefly, 200 µl of cell extract were placed into a 96 well Omega 186 
10 K filter plate (AcroPrep™, PALL Corporation, NY, USA) and then centrifuged for 15 187 
min at 2500×g. All samples and standards were incubated at 37°C overnight with 188 
chondroitinase B, heparitinase, and keratanase II (Seikagaku Co., Okyo, Japan). After 189 
incubation, the disaccharides were collected by centrifugation for 15 min at 2500 ×g, and 190 
analyzed by LC-MS/MS following a standardized protocol [35]. All assays were performed 191 
in triplicate. Experiments were carried out at Nemours/Alfred I. duPont Hospital for 192 
Children (Wilmington, DE, USA), under approved protocols. 193 
2.8 Enzyme biodistribution  194 
According to Tomatsu et al. [32], male C57BL/6 wild-type mice (7-8 weeks old) received a 195 
single intravenous administration of 1x PBS or 5 mg kg−1 of prGALNS labeled with 196 
AlexaFluor 568 (Molecular Probes, Thermo Fisher Scientific, San Jose, CA, USA). Mice 197 
were sacrificed at 12 and 24 h post-infusion. Brain, lung, heart, liver, spleen, kidney, and 198 
bone (femur) were collected and immersion-fixed in 10% neutral buffered formalin, 199 
embedded in paraffin and sectioned (Laboratory of Pathology, Hospital Universitario San 200 
Ignacio, Bogotá D.C., Colombia). Tissues were studied by fluorescence microscopy for 201 
enzyme distribution. All procedures were carried out at the Biology Comparative Unit at 202 
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Pontificia Universidad Javeriana, in accordance with the Institutional Animal Care and Use 203 
Committee guidelines under approved protocols. 204 
2.9 Immunization of mice and detection of anti-prGALNS antibodies.  205 
To evaluate immunogenicity of prGALNS, male C57BL/6 wild-type mice (7-8 weeks old) 206 
received 5 mg kg−1 of prGALNS or 1x PBS weekly during 4 weeks (n=5 per group). The 207 
prGALNS was diluted in 1x PBS and injected intravenously through the lateral tail vein. 208 
Blood samples were taken at 0, 15, and 30 days post-infusion. All procedures were carried 209 
out at the Biology Comparative Unit at Pontificia Universidad Javeriana, in accordance 210 
with the Institutional Animal Care and Use Committee guidelines under approved 211 
protocols. An indirect ELISA was used to determine antibody generation in serum from 212 
mice immunized with prGALNS. For this purpose, 96-well plates were coated overnight at 213 
37 °C with 10 µg mL-1 of purified prGALNS in PBS pH 7.4. Wells were blocked for 2 h at 214 
37°C with 1x PBS pH 7.4, 0.05% Tween 20 and 5% non-fat dry milk. The plates were 215 
washed two times with PBST (1x PBS pH7.4, 0.05% Tween 20). One hundred µL of serum 216 
dilutions, between 1:100 and 1:5000 in PBST and 5% non-fat dry milk, were added to the 217 
wells and incubated at 37 °C for 1 h. After three PBST washes, a peroxidase conjugated 218 
goat anti-mouse IgG (A9044 Sigma- Aldrich, St. Louis, MO, USA) was added to the wells 219 
in a 1:2000 dilution and plates were incubated at 37°C for 1 h. The reaction was developed 220 
with TMB Sure Blue substrate (KPL, Milford. MA, USA) and incubated at room 221 
temperature for 10 min. The reaction was stopped with 1N HCl and the plate was read at 222 
450 nm on an Anthos 2020 ELISA plate reader. 223 
2.10 Statistical analysis 224 
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Differences between groups were tested for statistical significance by using two-way 225 
ANOVA and Tukey’s multiple comparison test. An error level of 5% (p < 0.05) was 226 
considered significant. All analyses were performed using GraphPad Prism v.7.0 227 
(GraphPad Software, La Jolla, California, USA). All results are shown as mean ± SD. 228 
 229 
3. RESULTS AND DISCUSSION 230 
3.1 N-Glycosylation structure 231 
N-glycans analysis performed in the culture supernatant of wild-type P. pastoris GS115 232 
revealed a N-glycosylation profile consisting of a main peak of 9 mannose residues (M9) 233 
and subsequent peaks representing additional mannose residues (≥M10) (Figure 1B). In 234 
contrast, in the prGALNS-producing strain, a stronger hypermannosylation pattern was 235 
observed, characterized by an increase in the abundance of peaks corresponding to M10 and 236 
M11 (Figure 1C). The N-glycosylation pattern of the prGALNS-producing strain was 237 
characterized by the presence of signals that suggest either phospho-mannosyl 238 
phosphorylation (mono- or double-mannosyl phosphorylated N-glycans) or terminal 239 
phosphorylation (Figure 1C). A similar N-glycosylation pattern was observed for the strain 240 
co-expressing GALNS and SUMF1 (Figure 1D), suggesting that co-expression of SUMF1 241 
does not affect the N-glycosylation as observed in CHO-produced GALNS due to the 242 
changes in cell uptake of SUM1-activated GALNS [6]. Maltodextrin was used as glucose 243 
units reference (Figure 1A) and RNAse B N-glycans were used as reference for high-244 
mannose glycans (Figure 1E).  245 
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The Man8-15GlcNAc2 pattern observed in prGALNS agrees with previous reports for 246 
proteins produced in P. pastoris [26, 36]. This profile is closer to the mammalian N-247 
glycosylation than that observed in proteins produced in Saccharomyces cerevisiae, which 248 
is characterized by hypermannosylated glycan species (>Man50) [37, 38]. Nevertheless, the 249 
N-glycosylation pattern observed in P. pastoris GS115 evidenced several differences in 250 
terms of complexity with the typical mammalian N-glycosylation. For instance, in P. 251 
pastoris, the N-glycan structure is mainly composed by mannose; while mammalian N-252 
glycans display a variety of monosaccharide units in their structure, especially sialic acid, 253 
fucose, and galactose, among others [26, 39, 40]. As an additional finding, we observed the 254 
presence of phosphorylated glycans in prGALNS (Figure 1 C and D). However, 255 
phosphorylations reported in P. pastoris are characterized by capped 256 
mannosylphosphorylations contrasting to the typical mammalian terminal mannose-6-257 
phosphate residues [41]. For this reason, it has been proposed that Pichia derived proteins 258 
for therapeutic uses may need further enzymatic treatment to uncap and expose the M6P 259 
residues [41].   260 
N-glycosylation has been associated with stability, immunogenicity, internalization, 261 
efficacy, and biodistribution of proteins [42-44]. However, implications of the mentioned in 262 
N-glycosylation patterns between mammalian and P. pastoris GS115 are still not well 263 
understood [36]. Although yeast hypermannosylated N-glycans have been suggested to 264 
trigger immune response, no detailed study has been performed to evaluate such association 265 
[36]. Conversely, low amounts of oligomannose structures (Man5-9) have been reported in 266 
human plasma proteins [45], as well as in approved recombinant proteins for different 267 
lysosomal storage disorders [42, 44, 46].  The N-glycosylation profile of elosulfase alfa 268 
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revealed that the dominant N-glycan species are BisP-Man6, BisP-Man7, and non-269 
phosphorylated Man8 and Man9. In addition, no complex, hybrid glycans or other sialic acid 270 
containing glycans were also detected in elosulfase alfa [47]. Taken together, the N-glycans 271 
analysis of prGALNS confirm the potential of P. pastoris as expression system for the 272 
development of an alternative ERT for MPS IVA. These potential could be enhanced by 273 
tailoring the N-glycans [23], which could improve cell stability, cell uptake and therapeutic 274 
efficacy [41].  275 
 276 
3.2 Cell uptake and intracellular trafficking 277 
Previously, we reported that prGALNS can be internalized by human skin fibroblasts from 278 
unaffected individuals and HEK293 cells through a potential endocytic pathway [28]. Here, 279 
we further explored the mechanism for prGALNS internalization. Cell capture assays were 280 
performed in the presence of selective inhibitors of the main receptors associated with the 281 
internalization of lysosomal enzymes: M6PR or mannose receptor (MR) [7, 26, 32, 42, 44, 282 
48, 49]. The results suggest that prGALNS is internalized using both M6PR and MR, since 283 
addition of inhibitors for these receptors significantly reduced the cell uptake of the 284 
recombinant enzyme (Figure 2A).  285 
Based on the prGALNS N-glycosylation pattern described above, it was expected that the 286 
high content of oligomannose glycans favor interaction with the MR, which is in good 287 
agreement with the results observed for other lysosomal proteins produced in P. pastoris, 288 
plants, and moss [26, 50-52]. The role of the M6PR in the internalization of yeast produced 289 
enzymes, to the best of our knowledge, has not been directly assessed. This is of great 290 
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importance, especially considering that we observed peaks suggesting capped non-terminal 291 
phosphomannosyl glycans (D-mannose-α-1-phospho-6-D-mannose) in prGALNS (Figure 292 
1), which is similar to that reported for α-galactosidase and α-glucosidase produced in 293 
Pichia pastoris and Yarrowia lipolytica, respectively [41]. Nonetheless, further 294 
characterization of M6PR interactions with these types of mannosyl phosphorylations are 295 
required to better understand the internalization mechanism used by P. pastoris-produced 296 
enzymes.  297 
We observed that both M6PR and MR inhibitors did not abolish completely the prGALNS 298 
internalization (Figure 2A). These findings suggest that the enzyme may also be 299 
internalized through a M6PR/MR-independent pathway. Although other mechanisms have 300 
been proposed for lysosomal enzymes internalization, these remain poorly understood [53, 301 
54]. However, regardless of the mechanism, we observed that the internalized prGALNS 302 
co-localized with the lysosomal staining (Figure 2C, Pearson correlation R = 0.56), similar 303 
to previous reports for the recombinant GALNS produced in CHO cells [7, 55] and 304 
iduronate-2-sulfatase produced in P. pastoris [20].  305 
In the second stage, we explored the ability of prGALNS to be taken up by MPS IVA 306 
patients skin fibroblasts. As shown in Figure 2B, the cellular uptake of prGALNS in the 307 
fibroblasts showed a similar pattern to that reported for HEK293 cells [28], with clear 308 
increment in the intracellular GALNS activity post-treatment in a dose-dependent manner. 309 
However, this change was only statistically significant at the highest used dose of the 310 
recombinant enzyme (200 nM) in contrast to HEK293 where statistically significant 311 
differences were observed using 50 nM of prGALNS. Such behavior may reflect the 312 
differences that occur in the internalization ability of different cell types for the same 313 
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protein [56-59]. These differences have been associated with changes in expression level of 314 
receptors and the effect of N-glycosylation variants on the cellular uptake process [56-59].  315 
To evaluate the therapeutic potential of prGALNS, we measured the di-KS levels in MPS 316 
IVA skin fibroblasts treated with 50, 100, and 200 nM of prGALNS (equivalent to 6 to 24 317 
µg) . Similar amounts of recombinant GALNS produced in CHO cells were used both in-318 
vitro (0.78 to 200 nM) [7, 32] and in-vivo (0.24 to 24 µg) [6, 7]. As observed in Figure 3, 319 
there was a significant reduction in the intracellular di-KS levels after treatment with 320 
prGALNS for all of the evaluated doses. A reduction up to 81% of accumulated di-KS was 321 
obtained using 100 nM of prGALNS. Similar behavior was observed in MPS IVA 322 
chondrocytes with the enzyme produced in CHO cells (reduction of KS accumulation 80 – 323 
100%), using a lower enzyme concentration (1 and 10 nM), which might be related to the 324 
higher specific enzyme activity levels reported for that enzyme (120,000 U mg-1) [7]. 325 
Nonetheless, our results suggest that the P. pastoris-produced enzyme is not only 326 
structurally but also functionally similar to the human enzyme, which makes it a potential 327 
option for therapeutic purposes.   328 
 329 
3.3 Biodistribution  330 
We evaluated tissue distribution of prGALNS after a single IV of 5 mg kg-1 (83.5 U kg-1), 331 
in wild-type C57BL/6 mice. Twelve-hours post-treatment, it was observed that prGALNS 332 
was mainly localized in spleen, liver, and heart; while after 24 hours the enzyme was 333 
detected in spleen, heart, and kidney (Figure 4). There was no presence of the recombinant 334 
enzyme in brain, growth plate or bone tissue. These results suggest a rapid clearance of the 335 
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enzyme by highly perfused tissues, which is in agreement with a previous report of 336 
intravenous administration of recombinant GALNS produced in CHO cells [32]. In MPS 337 
IVA, the main affected tissues include cardiac valves, lung, and cartilage (growth plate), 338 
making these tissues the main target for any therapeutic approach [7, 8, 60]. Our results 339 
show that prGALNS preferentially reaches visceral organs. However, the therapeutic 340 
implications of such behavior might not be properly assessed by single infusion since other 341 
studies suggest that higher doses (10 mg/kg) and repeated administration may saturate the 342 
enzyme in liver and spleen and allow the distribution to other tissues [7].   343 
 344 
3.4 Generation of anti-prGALNS antibodies 345 
To analyze the generation of anti–prGALNS antibodies, wild-type C57BL/6 mice were 346 
weekly infused with 5 mg kg−1 of prGALNS and the anti-prGALNS antibodies were 347 
assayed after 15 and 30 days into the immunization regimen. Anti-prGALNS IgG 348 
antibodies were only evaluated, since this is the main isotype found in other studies using 349 
exogenous lysosomal enzymes in different animal species [61-63]. The results showed the 350 
production of anti-prGALNS antibodies with an increasing trend along time (Figure 5), as 351 
would be expected by the difference in human and mouse GALNS, since these proteins 352 
share a 85% identity [64]. The results are about one order of magnitude lower than those 353 
reported in C57Bl/6 MPS IVA knock-out mice infused with a recombinant GALNS 354 
produced in CHO cells [64]. Since a higher amount of protein was infused in the present 355 
study (5 mg kg-1) than in recombinant GALNS produced in CHO cells (about 1.5 mg kg-1), 356 
we can speculate that prGALNS could have a similar immunogenicity compared to CHO 357 
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cell-produced enzyme. In addition, similar results were observed in mice treated with a 358 
human recombinant lysosomal acid lipase (hLAL) produced in Nicotiana benthamiana [65]. 359 
The authors showed that anti-hLAL antibodies were produced against both glycosylated and 360 
deglycosylated recombinant hLAL, suggesting that that the antibodies are mainly produced against 361 
the protein backbone rather than to the N-glycans. A recent report showed that, in mice, similar 362 
antibodies titers are produced against plant-or mammalian-derived lysosomal α-L-363 
iduronidase [66]. In the same way, Kreer et. al. [67], developed a direct comparison of 364 
immunogenicity between N-glycosylated and. de-glycosylated proteins produced in Pichia 365 
pastoris. The results showed that N-glycosylated proteins neither influenced dendritic cells 366 
maturation nor their general capacity to activate T cells, pointing out that enforced N-367 
glycosylation does not increase the immunogenicity of an antigen per se. They also 368 
observed a strong IgG response after injection of de-glycosylated protein; while protein-369 
specific IgGs were hardly detectable after immunization with the N-glycosylated protein, 370 
suggesting that N-glycosylations may prevent MHC II-restricted presentation of the 371 
recombinant protein. Taken together, we consider that anti-prGALNS antibodies are mainly 372 
produced against protein backbone rather than to the N-glycans. Nevertheless, anti-GALNS 373 
antibodies have been reported in 100% of the patients treated with elosulfase alfa [13], 374 
suggesting that other factors could be involved in the immune response against the 375 
recombinant protein. However, up to now, there is no a clear correlation between antibody 376 
production and therapeutic efficacy of ERT [68]. In this sense, further studies are need to 377 
characterization antibody production against prGALNS produced, as well as studies 378 
addressing the effect of such antibodies on treatment response. 379 
 380 
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4. CONCLUSIONS 381 
In this study, we have characterized the N-glycosylation structure of a recombinant 382 
GALNS produced in the yeast P. pastoris GS115 and evaluated, in vitro and in vivo, some 383 
therapeutic characteristics of this recombinant enzyme. In vitro, it was observed that 384 
prGALNS presented mainly yeast-type high-mannose chains and mannosylphosphorylated 385 
derivatives thereof. This recombinant protein was successfully internalized by mammalian 386 
cells reaching the lysosome. The internalized enzyme was able to clear the stored 387 
intracellular di-KS in MPS IVA patients fibroblasts. In addition, the in-vivo results 388 
suggested that prGALNS is rapidly cleared from the organism. In summary, these findings 389 
show the potential of P. pastoris as a yeast platform for the production of a therapeutic 390 
human recombinant enzyme for MPS IVA. Future works should aim to improve the 391 
enzyme activity, as well as biodistribution and targeting of prGALNS to main affected 392 
tissues in MPS IV A. The rise of some level of anti-drug antibodies over time for this 393 
human protein in the mouse experimental model needs to be taken into account for long-394 
term treatment model studies. 395 
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Figure legends 586 
Figure 1. N-glycan profile of P. pastoris strains. A. Maltodextrin reference. B-D. N-587 
glycan profile of the proteins present in growth medium of P. pastoris GS115 (B) P. 588 
pastoris GS115::GALNS (C) and P. pastoris GS115::GALNS-SUMF1 (D). * 589 
monomannosyl phosphorylated N-glycans; ** double-mannosyl phosphorylated N-glycans. 590 
E. Reference N-glycans from bovine RNase B. 591 
Figure 2. Internalization and trafficking of prGALNS in mammalian cells. A. Cellular 592 
uptake assayed in cultured HEK293 after treatment with 50 nM prGALNS with and 593 
without inhibitors. B. Cellular uptake assayed in MPS IVA patients fibroblasts after 594 
treatment with different concentrations of prGALNS. Assays were performed in by 595 
triplicate. * p < 0.05. C. Intracellular trafficking in HEK293 cells treated with prGALNS 596 
labeled with Alexa Fluor 568. Scale bar 50µm. Pearson correlation value was calculated by 597 
Fiji (Image J) with R = 0.56 (above threshold) and thresholded Mander's coefficients tM1 598 
and tM2 were 0.975 and 0.533, respectively.  599 
Figure 3. Quantitation of KS in MPS IVA fibroblasts treated with prGALNS. MPS 600 
IVA patient skin fibroblast were treated with 50, 100, and 200 nM of prGALNS and the KS 601 
levels were quantified by LC-MS/MS. Results are reported as fold to untreated MPS IVA 602 
fibroblast (blue). * p < 0.05 . 603 
Figure 4. Biodistribution of prGALNS. Male C57BL/6 mice (7-8 weeks old) received a 604 
single intravenous administration of 1x PBS (control) or 5 mg kg−1 of prGALNS labeled 605 
with AlexaFluor 568 Histological sections of spleen, liver, heart and kidney were taken at 606 
12 and 24 h post-treatment. Scale bar 100µm. 607 
Figure 5. Generation of anti-prGALNS antibodies. Wild-type C57BL/6 mice were 608 
weekly infused 1x PBS or 5 mg kg−1 of prGALNS and the anti-prGALNS antibodies were 609 
assayed in serum samples after 15 and 30 days into the immunization regimen (n=5 per 610 
group). 611 
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